Transmucosal Drug Delivery Devices intended for the localized delivery of medications through a mucous membrane. Usually, drugs are administered through buccal, rectal, vaginal, and nasal routes. GlobalData's Medical Devices sector report, “Transmucosal Drug Delivery Devices – Medical Devices Pipeline Assessment, 2019" provides comprehensive information about the Transmucosal Drug Delivery Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Transmucosal Drug Delivery Devices Pipeline Assessment report provides key information and data related to:
Extensive coverage of the Transmucosal Drug Delivery Devices under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Transmucosal Drug Delivery Devices pipeline products.
Review of Recent Developments in the segment / industry
The Transmucosal Drug Delivery Devices Pipeline Assessment report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Transmucosal Drug Delivery Devices under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2009 and forecast to 2023
• 4,500+ industry-leading analysis and procedure reports covering growing sectors, market trends, investment opportunities and competitive landscape
• 56,000+ medical equipment company profiles
• 4,300+ company profiles of medical equipment manufacturers in China and India
• 2,000+ company profiles of medical equipment manufacturers in Japan
• 825+ companies’ revenue splits and market shares
• 1,900+ quarterly and annual medical equipment company financials
• 940+ medical equipment company SWOTs
• 21,500+ pipeline product profiles
• 34,500+ marketed product profiles
• 36,000+ clinical trials
• 36,500+ trial investigators
• 5,400+ reports on companies with products in development
• 33,000+ deals in the medical equipment industry
• 1,300+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.
Scope
– Extensive coverage of the Transmucosal Drug Delivery Devices under development
– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
– The report reviews the major players involved in the development of Transmucosal Drug Delivery Devices and list all their pipeline projects
– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
– The report provides key clinical trial data of ongoing trials specific to pipeline products
– Recent developments in the segment / industry
Reasons to buy
The report enables you to:
– Formulate significant competitor information, analysis, and insights to improve R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of Transmucosal Drug Delivery Devices under development
– Develop market-entry and market expansion strategies
– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
– In-depth analysis of the product’s current stage of development, territory and estimated launch date
'
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 16
2 Introduction 17
2.1 Transmucosal Drug Delivery Devices Overview 17
3 Products under Development 18
3.1 Transmucosal Drug Delivery Devices – Pipeline Products by Stage of Development 18
3.2 Transmucosal Drug Delivery Devices – Pipeline Products by Segment 19
3.3 Transmucosal Drug Delivery Devices – Pipeline Products by Territory 20
3.4 Transmucosal Drug Delivery Devices – Pipeline Products by Regulatory Path 22
3.5 Transmucosal Drug Delivery Devices – Pipeline Products by Estimated Approval Date 23
3.6 Transmucosal Drug Delivery Devices – Ongoing Clinical Trials 24
4 Transmucosal Drug Delivery Devices – Pipeline Products under Development by Companies 25
4.1 Transmucosal Drug Delivery Devices Companies – Pipeline Products by Stage of Development 25
4.2 Transmucosal Drug Delivery Devices – Pipeline Products by Stage of Development 28
5 Transmucosal Drug Delivery Devices Companies and Product Overview 32
5.1 AcelRx Pharmaceuticals Inc Company Overview 32
5.1.1 AcelRx Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 32
5.2 Aegis Therapeutics LLC Company Overview 37
5.2.1 Aegis Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 37
5.3 AFYX Therapeutics A/S Company Overview 40
5.3.1 AFYX Therapeutics A/S Pipeline Products & Ongoing Clinical Trials Overview 40
5.4 Albert Einstein College of Medicine Company Overview 43
5.4.1 Albert Einstein College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 43
5.5 Allergan Plc Company Overview 44
5.5.1 Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 44
5.6 Amphastar Pharmaceuticals Inc Company Overview 45
5.6.1 Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45
5.7 Aquestive Therapeutics Inc Company Overview 46
5.7.1 Aquestive Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 46
5.8 ARS Pharmaceuticals Inc Company Overview 52
5.8.1 ARS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 52
5.9 Auritec Pharmaceuticals Inc Company Overview 53
5.9.1 Auritec Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 53
5.10 BeFree! Company Overview 59
5.10.1 BeFree! Pipeline Products & Ongoing Clinical Trials Overview 59
5.11 Bespak Europe Ltd Company Overview 60
5.11.1 Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
5.12 Biorings LLC Company Overview 62
5.12.1 Biorings LLC Pipeline Products & Ongoing Clinical Trials Overview 62
5.13 BioXcel Therapeutics Inc Company Overview 63
5.13.1 BioXcel Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.14 Callitas Therapeutics Inc Company Overview 66
5.14.1 Callitas Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 66
5.15 Columbia University Company Overview 67
5.15.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 67
5.16 Combinent BioMedical Systems Inc Company Overview 68
5.16.1 Combinent BioMedical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.17 Conrad Company Overview 69
5.17.1 Conrad Pipeline Products & Ongoing Clinical Trials Overview 69
5.18 Dare Bioscience Inc Company Overview 73
5.18.1 Dare Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.19 Emergent BioSolutions Inc Company Overview 79
5.19.1 Emergent BioSolutions Inc Pipeline Products & Ongoing Clinical Trials Overview 79
5.20 Evestra Inc Company Overview 80
5.20.1 Evestra Inc Pipeline Products & Ongoing Clinical Trials Overview 80
5.21 Evofem Biosciences Inc Company Overview 84
5.21.1 Evofem Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 84
5.22 Evoke Pharma Inc Company Overview 85
5.22.1 Evoke Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.23 EyeGate Pharmaceuticals Inc Company Overview 86
5.23.1 EyeGate Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 86
5.24 Ferring Pharmaceuticals AS Company Overview 88
5.24.1 Ferring Pharmaceuticals AS Pipeline Products & Ongoing Clinical Trials Overview 88
5.25 Ghent University Company Overview 90
5.25.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 90
5.26 Glenmark Pharmaceuticals Ltd Company Overview 91
5.26.1 Glenmark Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 91
5.27 Hebrew University of Jerusalem Company Overview 92
5.27.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 92
5.28 INSYS Therapeutics Inc Company Overview 93
5.28.1 INSYS Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 93
5.29 IntelGenx Corp Company Overview 97
5.29.1 IntelGenx Corp Pipeline Products & Ongoing Clinical Trials Overview 97
5.30 Janssen Research & Development LLC Company Overview 100
5.30.1 Janssen Research & Development LLC Pipeline Products & Ongoing Clinical Trials Overview 100
5.31 Karessa Pharma AB Company Overview 101
5.31.1 Karessa Pharma AB Pipeline Products & Ongoing Clinical Trials Overview 101
5.32 Kytogenics Pharmaceuticals Inc Company Overview 104
5.32.1 Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 104
5.33 Laboratoire HRA Pharma SAS Company Overview 105
5.33.1 Laboratoire HRA Pharma SAS Pipeline Products & Ongoing Clinical Trials Overview 105
5.34 Laboratorios Andromaco Company Overview 106
5.34.1 Laboratorios Andromaco Pipeline Products & Ongoing Clinical Trials Overview 106
5.35 Lyra Therapeutics Company Overview 107
5.35.1 Lyra Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 107
5.36 McNeil AB Company Overview 108
5.36.1 McNeil AB Pipeline Products & Ongoing Clinical Trials Overview 108
5.37 Medlab Clinical Ltd Company Overview 109
5.37.1 Medlab Clinical Ltd Pipeline Products & Ongoing Clinical Trials Overview 109
5.38 Merck & Co Inc Company Overview 110
5.38.1 Merck & Co Inc Pipeline Products & Ongoing Clinical Trials Overview 110
5.39 Merck Serono SA Company Overview 112
5.39.1 Merck Serono SA Pipeline Products & Ongoing Clinical Trials Overview 112
5.40 Merck Sharp & Dohme Ltd Company Overview 113
5.40.1 Merck Sharp & Dohme Ltd Pipeline Products & Ongoing Clinical Trials Overview 113
5.41 Mithra Pharmaceuticals SA Company Overview 114
5.41.1 Mithra Pharmaceuticals SA Pipeline Products & Ongoing Clinical Trials Overview 114
5.42 Mystic Pharmaceuticals Inc Company Overview 115
5.42.1 Mystic Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 115
5.43 Nanosys Inc Company Overview 117
5.43.1 Nanosys Inc Pipeline Products & Ongoing Clinical Trials Overview 117
5.44 NorInvent AB Company Overview 118
5.44.1 NorInvent AB Pipeline Products & Ongoing Clinical Trials Overview 118
5.45 Novus Therapeutics Inc Company Overview 119
5.45.1 Novus Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 119
5.46 Oak Crest Institute of Science Company Overview 122
5.46.1 Oak Crest Institute of Science Pipeline Products & Ongoing Clinical Trials Overview 122
5.47 Opiant Pharmaceuticals Inc Company Overview 123
6.135 Jul 31, 2018: Marinomed Biotech names Pascal Schmidt as CFO 272
6.136 Jul 30, 2018: BioDelivery Sciences appoints Thomas Smith, MD as chief medical officer further expanding company’s expertise in field of pain management 273
6.137 Jul 26, 2018: Cosmo Half-Year report 2018 274
6.138 Jul 23, 2018: Dermtreat Announces First Patient Dosed in Phase 2b Clinical Trial of Rivelin Clobetasol for Oral Lichen Planus 275
6.139 Jul 20, 2018: Mithra obtains first Marketing Authorization for Myring in Europe 276
6.140 Jul 17, 2018: Orion Biotechnology awarded a $2M grant from National Center for Research and Development to fund further development of its HIV microbicide 276
6.141 Jul 13, 2018: Indivior Is Granted Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film 277
6.142 Jun 27, 2018: AcelRx receives European Commission approval for DZUVEO 278
6.143 Jun 27, 2018: BioXcel Therapeutics reports positive results from phase 1b trial of intravenously-dosed Dexmedetomidine supporting BXCL501 development 278
6.144 Jun 26, 2018: Albertsons Companies Offers Increased Access to Naloxone 279
6.145 Jun 25, 2018: Opiant Pharmaceuticals announces receipt of first tranche from National Institutes of Health Grant for development of OPNT003, intranasal Nalmefene, for treatment of opioid overdose 280
6.146 Jun 25, 2018: Generex Names Terry Thompson As Chief Operating Officer 280
6.147 Jun 21, 2018: Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals 281
6.148 Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media 283
6.149 Jun 15, 2018: Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market 284
6.150 Jun 14, 2018: Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection 284
6.151 Jun 14, 2018: Consort Medical delivered another year of good growth in revenue and profit 285
6.152 Jun 13, 2018: Sonoma Pharmaceuticals Announces Fiscal Year And Fourth Quarter 2018 Financial Results 288
6.153 Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 290
6.154 Jun 04, 2018: Dare Bioscience Appoints Mary Jarosz To Global Head Of Regulatory Affairs 290
6.155 Jun 04, 2018: RDD Pharma Names Dr. Mark Sirgo As Chairman Of The Board Of Directors 291
6.156 May 29, 2018: Egalet Announces Large Regional Plan to Cover SPRIX Nasal Spray 291
6.157 May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN 292
6.158 May 24, 2018: AcelRx announces FDA acceptance of NDA for DSUVIA 292
6.159 May 21, 2018: Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps 293
6.160 May 21, 2018: Glenmark Pharmaceuticals announces the company's first new drug application for Ryaltris for patients with seasonal allergic rhinitis 293
6.161 May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting 294
6.162 May 15, 2018: Dare Bioscience Announces Trial Initiation for Ovaprene Non-Hormonal Monthly Contraceptive Candidate 296
6.163 May 14, 2018: Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case 296
6.164 May 14, 2018: Corium Announces Second Quarter Fiscal 2018 Financial Results 297
7 Appendix 299
7.1 Methodology 299
7.2 About GlobalData 302
7.3 Contact Us 302
7.4 Disclaimer 302
